Home  >  Products  >  NLRP3 (NLR family, pyrin domain containing 3 ) Blocking Peptide (the N terminal of NLRP3)(100ug)
NLRP3 (NLR family, pyrin domain containing 3 ) Blocking Peptide (the N terminal of NLRP3)(100ug)

NLRP3 (NLR family, pyrin domain containing 3 ) Blocking Peptide (the N terminal of NLRP3)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-NLRP3 Antibody (ARP63297_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP63297
Size: 100ug
Weight: 114kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: This gene encodes a pyrin-like protein containing a pyrin domain, a nucleotide-binding site (NBS) domain, and a leucine-rich repeat (LRR) motif. This protein interacts with the apoptosis-associated speck-like protein PYCARD/ASC, which contains a caspase recruitment domain, and is a member of the NALP3 inflammasome complex. This complex functions as an upstream activator of NF-kappaB signaling, and it plays a role in the regulation of inflammation, the immune response, and apoptosis. Mutations in this gene are associated with familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous and articular (CINCA) syndrome, and neonatal-onset multisystem inflammatory disease (NOMID).
Alternative names: AGTAVPRL; AII; AII/AVP; AVP; C1orf7; CIAS1; CLR1.1; FCAS; FCU; FLJ95925; MWS; NALP3; PYPAF1
See Full Product Listings >